Doctor Trial Results – Our study has shown that tailoring therapy for oesophageal cancer is feasible and merits further study.
Background: Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) to chemotherapy have poorer survival and histological response rates <5%. We investigated whether tailoring neoadjuvant therapy can improve outcomes in these patients. Patients and methods: Patients with resectable EAC were …
In the operating theatre with Dr Bas Wijnhoven
In the operating theatre with dr Bas Wijnhoven (upper Gastrointestinal surgeon) who came to visit us from Rotterdam for the week.
13th International Gastric Cancer Congress
Invited presentation at the International Gastric Cancer Congress, Prague 2019. I was asked to discuss the use of PET scans as a predictor or treatment benefit in cancer of the stomach and oesophagus based on our experience with the DOCTOR trial.